组织型纤溶酶原激活剂

野生型组织型纤溶酶原激活剂（t-PA）工程细胞株生物学特性分析

The analysis of biological characteristics for the wild-type t-PA engineering cell lines

视网膜静脉微穿刺注入组织型纤溶酶原激活剂治疗视网膜静脉阻塞的实验研究

Experiment study of infusing tPA in retinal vein for treatment of retinal vein occlusion

定量检测组织型纤溶酶原激活剂夹心ELISA方法的建立

Establishment of a Sandwich ELISA for Quantitative Measurement of Tissue-type Plasminogen Activator

EGF对小鼠角质形成细胞中组织型纤溶酶原激活剂表达的调节

Regulation of tissue plasminogen activator expression by EGF in epidermal keratinocytes of mouse

MCF-7细胞中组织型纤溶酶原激活剂乳腺特异性表达载体的瞬时表达

Transient expression of tissue-type plasminogen activator in mammary carcinoma cell line MCF-7

组织型纤溶酶原激活剂（t-PA）及其突变体的表达研究进展

Progresses in the Expression of Tissue-Type Plasminogen Activator and Its Mutants

组织型纤溶酶原激活剂（t-PA）、纤溶酶原激活剂抑制剂（PAI）均是体内纤溶系统的重要组成部分。

PAI and t-PA are important constituents of fibrinolytic system in human body .

载脂蛋白AI、组织型纤溶酶原激活剂显著低于对照组（P＜0.001和P＜0.01）。

The concentration of Apo A I and t PA activity were obviously lower than those of the controls ( p < 0 001 and 0 01 , respectively ) .

组织型纤溶酶原激活剂&膜联蛋白A5融合基因的构建

Construction of Tissue Plasminogen Activator-annexin A5 Fusion Gene

组织型纤溶酶原激活剂（t-PA）对实验性青光眼滤过性手术瘢痕形成的影响

Effects of tissue plasminogen activator ( t-PA ) on scar formation after experimental filtration surgery

采用尿激酶（75万~150万U）或重组组织型纤溶酶原激活剂（50~100mg）溶栓。

Urokinase ( 750 ? 000 U-1 ? 500 ? 000 U ) and recombinant tissue-type plasminogen activator ( 50-100 mg ) were administered as thrombolytic agents .

本文建立了组织型纤溶酶原激活剂（t-PA）活力的发光固相测定方法。

A luminescence solid phase assay for tissue type plasminogen activator ( t-PA ) was developed .

目的研究兔角膜碱烧伤后修复过程中，组织型纤溶酶原激活剂（tPA）和2型纤溶酶原激活剂抑制剂（PAI2）的作用。

Objective To explore the function of tPA and PAI-2 in the course of corneal repair after alkali burn .

本文用尿激酶（UK）和人体组织型纤溶酶原激活剂（t-PA）进行了兔髂股动脉血栓实验性溶解的对照研究。

The thrombolytic effect was compared between urokinase ( UK ) and human tissue plasminogen activator ( t-PA ) in rabbits with experimental iliofemoral artery thrombus .

采用发色底物分析法检测血浆组织型纤溶酶原激活剂（t－PA）及其抑制物（PAI）的活性及P／t比值。

Chromogenic peptide substrate analytical method was used to detect plasma tissue plasminogen activator ( t-PA ), tissue plasminogen activator inhibitor ( PAI ) activity and ratio of P / t.

目的比较小剂量重组组织型纤溶酶原激活剂（rtPA）与直接冠状动脉（冠脉）支架术治疗急性心肌梗死（AMI）的临床疗效。

Objective To compare the efficacy of low dose recombinant tissue-type plasminogen activator ( rt-PA ) thrombolysis with primary coronary stenting after acute myocardial infarction ( AMI ) .

微血管病变组、大血管病变组的纤溶酶原激活剂抑制物、组织型纤溶酶原激活剂、和纤维蛋白原高于对照组（P0.01）。

The serum levels of plasminogen activator inhibitor-1 , tissue plasminogen activator and fibrinogen were significantly increased in MI , MA groups ( P0.01 ) than those in controls .

目的探讨组织型纤溶酶原激活剂（tPA）参与人表皮角质形成细胞（KC）分化调控的作用。

Objective To explore the regulating roles of tissue-type plasminogen activator ( tPA ) in the differentiation of keratinocyte in the human epidermis .

被感染的受体细胞NIH3T3高效表达具有纤溶活性的重组人组织型纤溶酶原激活剂。

The expression oft-PA was demonstrated in the NIH3T3 cells infected with the recombinant virus .

目的探讨国人应用重组组织型纤溶酶原激活剂（rt-PA）溶栓治疗急性心肌梗死（AMI）的合适剂量。

Objective The aim of the study was to quest appropriate dose of recombinant tissue-type plasminogen activator ( rt-PA ) on Chinese patients with acute myocardial infarction .

目的探讨重组组织型纤溶酶原激活剂（rt-PA）治疗急性脑梗死的有效性和安全性。

Objective To discuss the efficiency and safety of recombinant tissue plasminogen activator ( rt-PA ) for patients with acute cerebral infarction .

westernblot定量分析心房心肌纤溶酶原激活剂抑制物1（PAI1）和组织型纤溶酶原激活剂（tPA）蛋白表达；

The expression of plasminogen activator inhibitor-1 ( PAI-1 ) and tissue-type plasminogen activator ( tPA ) protein in atrium was determined by Western Blot analysis and immunohistochemical staining .

目的进一步认识重组组织型纤溶酶原激活剂（rtPA）与尿激酶（UK）静脉溶栓治疗急性心肌梗死（AMI）疗效和安全性的差异。

Objective To further recognize the differences of efficacy and safety of intravenous thrombolysis with recombinant tissue plasminogen activator ( rt-PA ) vs urokinase ( UK ) in treatment of acute myocardial infarction ( AMI ) .

目的探讨小鼠表皮角质形成细胞（KC）中Ca~（2＋）对组织型纤溶酶原激活剂（tPA）表达的调节作用及其与分化的关系。

Objective To explore the regulation of calcium on the expression of tissue plasminogen activator ( tPA ) and its relationship with cell differentiation in mouse epidermal keratinocyte ( KC ) .

人Bowes黑色素瘤细胞的培养液中组织型纤溶酶原激活剂的提纯

Purification of human tissue-type plasminogen activator ( t-pa ) from human Bowes melanoma cell culture

用肝素、右旋糖酐和聚乙二醇对重组组织型纤溶酶原激活剂（rt-PA）进行化学修饰。不同的化学修饰物对rt-PA体外纤维蛋白溶解活性的影响不同。

Chemical modification of surface amino groups of recombinant tissue-type plasminogen activator ( rt-PA ) with heparin , polyethylene glycol ( PEG ) and dextran was conducted .

两种组织型纤溶酶原激活剂缺失突变体（r-PA）治疗实验性兔视网膜动脉阻塞

Intravenous Thrombolysis by Tissue-type Plasminogen Activator Deletion Mutant in a Rabbit Model of Retinal Artery Occlusion

目的构建组织型纤溶酶原激活剂（t-PA）乳腺定位表达载体，使其在牛乳汁中高效表达，从而建立牛乳腺生物反应器。

Objective To construct an expression vector for highly efficient expression of tissue-type plasminogen activator ( t-PA ) confined in the mammary gland of cow to develop a cow mammary gland bioreactor .

目的观察重组人组织型纤溶酶原激活剂缺失变体（reteplase）对犬冠状动脉血栓的溶栓作用。

Objective To observe the thrombolysis effects of recombinant human tissue type plasminogen activator ( Reteplase ) on coronary artery thrombosis in dogs .

目的探讨使用重组组织型纤溶酶原激活剂（rt-PA）动静脉联合溶栓治疗急性缺血性卒中的临床疗效及安全性。

Objective To investigate the clinical efficacy and safety of combined intravenous and intra-arterial infusion of recombinant tissue plasminogen activator ( rt-PA ) for treatment of acute ischemic stroke .